Study: Generic Drug Industry Embraces Faster, Cheaper Pathway For Challenging Patents image

Intellectual Property Watch, September 6, 2018
William New, quoting Jonathan Darrow (Student Fellow Alumnus)


Read the full article

From the article: 

A newly released study shows that generic drug companies win nearly half the time when challenging patents on United States government-approved pharmaceutical products through the Patent Trial and Appeal Board (PTAB) process.

The study, entitled, “The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents,” was published in “Applied Health Economics and Health Policy.” The authors are: Jonathan J. Darrow, S.J.D., J.D., M.B.A., Reed F. Beall, Ph.D., and Aaron S. Kesselheim M.D., J.D., M.P.H.

Read more here!

pharmaceuticals regulation